OmniAb (OABI) Resumen de Acciones
OmniAb, Inc. es una empresa biotecnológica que concede licencias de tecnología de investigación de descubrimientos a empresas farmacéuticas y biotecnológicas y a instituciones académicas para posibilitar el descubrimiento de terapias en Estados Unidos, Europa, Japón, China y Canadá. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
OABI Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de OmniAb, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$4.30 |
| Máximo en las últimas 52 semanas | US$4.59 |
| Mínimo de 52 semanas | US$1.30 |
| Beta | 1.22 |
| Cambio en 1 mes | 105.74% |
| Variación en 3 meses | 62.26% |
| Cambio de 1 año | 138.89% |
| Variación en 3 años | -24.69% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -51.90% |
Noticias y actualizaciones recientes
Seeking Alpha • Aug 18
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
Summary OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI’s 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI’s technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M. Valuation remains at a premium (11–14x sales), reflecting platform scalability and optionality, with key near-term catalysts from partner clinical readouts and program graduations. Read the full article on Seeking AlphaArtículo de análisis • Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI)
Celebrations may be in order for OmniAb, Inc. ( NASDAQ:OABI ) shareholders, with the analysts delivering a significant...Recent updates
Seeking Alpha • Aug 18
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
Summary OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI’s 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI’s technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M. Valuation remains at a premium (11–14x sales), reflecting platform scalability and optionality, with key near-term catalysts from partner clinical readouts and program graduations. Read the full article on Seeking AlphaArtículo de análisis • Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI)
Celebrations may be in order for OmniAb, Inc. ( NASDAQ:OABI ) shareholders, with the analysts delivering a significant...Artículo de análisis • Jun 30
We're Not Very Worried About OmniAb's (NASDAQ:OABI) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Actualización de narrativa • Jun 15
OABI: 2026 Revenue Guidance Update Will Support Long Term Upside Potential
Analysts have kept their $7.33 price target on OmniAb broadly unchanged, citing only minor tweaks to discount rate, revenue growth, profit margin assumptions and a future P/E of about 159x that leave their overall valuation view steady. What's in the News OmniAb issued updated earnings guidance for 2026, providing a new revenue range of $28 million to $33 million.Actualización de narrativa • Jun 01
OABI: 2026 Revenue Guidance Will Shape Long Term Upside Potential
Analysts have nudged their price target on OmniAb slightly higher to $7.33, reflecting updated assumptions around the company’s discount rate, long term revenue growth, profit margin, and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, projecting revenue in a range of $25 million to $30 million.Actualización de narrativa • May 15
OABI: 2026 Revenue Guidance And Margin Outlook Will Drive Long Term Upside
Analysts have updated their price target on OmniAb, maintaining their fair value estimate at $7.33 while refining assumptions for the discount rate, revenue growth, profit margins, and future P/E to reflect revised expectations for the business. What's in the News OmniAb issued earnings guidance for 2026, setting an expected revenue range of US$25 million to US$30 million.Actualización de narrativa • Apr 27
OABI: Updated Bylaws And 2026 Guidance Will Support Long Term Upside
Analysts have nudged their OmniAb price target slightly higher to $170.16 from $162.92, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million.Actualización de narrativa • Apr 08
OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside
Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).Actualización de narrativa • Mar 25
OABI: Updated Governance And 2026 Revenue Outlook Will Support Long Term Upside
Analysts kept their fair value estimate for OmniAb steady at $7.33 while making only very small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a largely unchanged view of the stock’s longer term risk and earnings potential.Actualización de narrativa • Mar 08
OABI: New Discovery Platform And Guidance Will Support Long Term Upside Potential
Analysts have modestly revised their price target on OmniAb, reflecting updated assumptions around long term revenue growth, profit margins, and future P/E expectations. Specific dollar values for the target change have not been disclosed.Actualización de narrativa • Feb 21
OABI: New Discovery Platform Will Support Stronger Long Term Upside Potential
Analysts have lowered their Omn iAb price target to $7.33 per share, citing slightly reduced profit margin assumptions and a modestly higher future P/E multiple, while keeping long-term revenue growth expectations broadly unchanged. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that became effective the same day, updating the company’s governance framework.Actualización de narrativa • Feb 06
OABI: New Antibody Platform And Governance Changes Will Drive Future Upside
Analysts have modestly trimmed their price targets on OmniAb, citing slightly higher discount rate assumptions along with a small uplift in expected profit margins and future P/E levels as the key drivers of the recalibration. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that took effect the same day, updating company rules and governance procedures.Actualización de narrativa • Jan 22
OABI: New Antibody Discovery Platform And Partnerships Will Drive Future Upside
Analysts have maintained their OmniAb price target at US$7.33, making only minor adjustments to assumptions such as the discount rate, long-term profit margin, and future P/E. These changes fine tune their valuation view rather than significantly revising it.Actualización de narrativa • Jan 08
OABI: New Antibody Platform Launch Will Drive Future Upside Potential
Analysts have lifted their price target on OmniAb to reflect updated assumptions for revenue growth of 41.53%, profit margin of 15.66% and a future P/E of 173.35x, which together suggest a slightly higher required return of 7.93% compared with prior inputs. What's in the News OmniAb launched its new OmniUltra platform at the 2025 Antibody Engineering & Therapeutics Conference in San Diego, describing it as a transgenic chicken system designed to generate human antibodies with ultralong CDRH3 domains and very small picobodies for a range of therapeutic uses, including bispecifics, multispecifics, CAR-T, radioligands and peptide therapeutics (Key Developments).Actualización de narrativa • Dec 16
OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside
Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.Actualización de narrativa • Dec 02
OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead
OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.Actualización de narrativa • Nov 18
OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside
Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.Artículo de análisis • Oct 10
OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...Artículo de análisis • Aug 09
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
NasdaqGM:OABI 1 Year Share Price vs Fair Value Explore OmniAb's Fair Values from the Community and select yours...Artículo de análisis • Jul 09
Market Participants Recognise OmniAb, Inc.'s (NASDAQ:OABI) Revenues Pushing Shares 38% Higher
OmniAb, Inc. ( NASDAQ:OABI ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...Artículo de análisis • May 11
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
It's shaping up to be a tough period for OmniAb, Inc. ( NASDAQ:OABI ), which a week ago released some disappointing...Artículo de análisis • Apr 20
OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, OmniAb, Inc. ( NASDAQ:OABI ) shares are down a considerable 29% in the last...
Nueva narrativa • Mar 29
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.Artículo de análisis • Nov 15
OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...Artículo de análisis • Sep 14
Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Artículo de análisis • Jul 15
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Key Insights OmniAb's estimated fair value is US$7.87 based on 2 Stage Free Cash Flow to Equity Current share price of...Artículo de análisis • May 12
The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
OmniAb, Inc. ( NASDAQ:OABI ) just released its latest quarterly report and things are not looking great. It was not a...Artículo de análisis • Mar 26
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Today is shaping up negative for OmniAb, Inc. ( NASDAQ:OABI ) shareholders, with the analysts delivering a substantial...Artículo de análisis • Feb 28
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...Artículo de análisis • Jan 15
OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Key Insights The projected fair value for OmniAb is US$8.52 based on 2 Stage Free Cash Flow to Equity OmniAb's US$6.22...Artículo de análisis • Nov 11
Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 7.6x may look like a poor investment opportunity when...Artículo de análisis • Aug 13
Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...Artículo de análisis • May 14
OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on OmniAb, Inc. ( NASDAQ:OABI ) - they aren't optimistic, having just made a...Rentabilidad de los accionistas
| OABI | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 25.4% | 2.6% | -0.8% |
| 1Y | 138.9% | 23.0% | 20.5% |
Rentabilidad vs. Industria: OABI superó a la industria US Life Sciences, que obtuvo un rendimiento del 23% el año pasado.
Rentabilidad vs. Mercado: OABI superó al mercado US, que obtuvo un rendimiento del 20.5% el año pasado.
Volatilidad de los precios
| OABI volatility | |
|---|---|
| OABI Average Weekly Movement | 14.7% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de OABI ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de OABI(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2012 | 89 | Matt Foehr | www.omniab.com |
OmniAb, Inc. es una empresa de biotecnología que concede licencias de tecnología de investigación de descubrimientos a empresas farmacéuticas y biotecnológicas y a instituciones académicas para posibilitar el descubrimiento de terapias en Estados Unidos, Europa, Japón, China y Canadá. La plataforma tecnológica de la empresa crea y criba diversos repertorios de anticuerpos para identificar anticuerpos óptimos y otras proteínas de unión a dianas para los esfuerzos de desarrollo de fármacos de sus socios. La inteligencia biológica de su plataforma OmniAb potencia los sistemas inmunitarios de sus animales transgénicos patentados y modificados para crear anticuerpos candidatos optimizados para terapias humanas.
Resumen de fundamentos de OmniAb, Inc.
| Estadísticas fundamentales de OABI | |
|---|---|
| Capitalización bursátil | US$609.19m |
| Beneficios(TTM) | -US$44.27m |
| Ingresos (TTM) | US$38.46m |
16.3x
Ratio precio-ventas (PS)-14.1x
Ratio precio-beneficio (PE)¿Está OABI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de OABI | |
|---|---|
| Ingresos | US$38.46m |
| Coste de los ingresos | US$663.00k |
| Beneficio bruto | US$37.79m |
| Otros gastos | US$82.06m |
| Beneficios | -US$44.27m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.30 |
| Margen bruto | 98.28% |
| Margen de beneficio neto | -115.12% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado OABI a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/20 00:35 |
| Precio de las acciones al final del día | 2026/08/20 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
OmniAb, Inc. está cubierta por 9 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |